Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

rwwine,

Back in 2016 I was reading the pre ASCO abstracts and Trillium had what I thought a very exciting CD-47 phase abstract with the drug used by way of Inter-tumor injection. I bought 2K shares prior to the meeting in the $7 range. The conference was a huge success and within a couple of months the topped out around $16. The stock then started dropping as rumors of other companies having toxic problems. I sold everything in the $12 range.

A couple of months later, the biggest player with CD47 was Celgene and they dropped their entire program because of side effects. This crushed everyone.

In late 2018 I saw that Tril was trading in the $3 range and decided that that was not right so I bought 1K shares just so I could watch it. Well that was a bad trade because the stock went from that $3 price down to around $.24.

In the first week of December 2019 Novartis announce the purchase of Arqule for $20 per share which I had a rather large holding with a basis of less than $3 but the majority of shares were short-term so I was going to get killed with taxes.

That morning I sold my Arqule and spread the proceeds around my existing stocks and while looking at my statement every stock I owned was green except Tril and that had a whopping 93% loss and was only worth around $250 dollars. At this point they were in non-compliance with Nasdaq's minimum price rules and I thought they would have to do a reverse split. All I was hoping for is that Tril would gain a nickel and if I bought enough I could get out even. I also figured the $15K investment was $8K of my money and $7K of Uncle Sam's because of taxes if the trade went bad.

Within a week of my Investment, a Company called FortySeven came out with some very interesting results on their CD47 drug and while they went from around $8 to $35 Tril went up to about $1.50. About a week later Tril made a announcement with very positive results and they jumped into the $2 range. A couple of weeks later Gilead stepped in and bought FortySeven for $4.9 Bil or $90 a share.

This was all happening in January of this year. Next, Tril did a $100 mil dollar raise with only biotech funds allowed to buy and the big boys bought in. Every raise Tril has done has been met with joy because they have been held back because of lack of cash.

When I first bought back they had $13 mil in cash and today they have $350 mil. Their MarketCap in December 2019 was $13 mil and today is $1.4 Billion

What I would suggest you look at is the CD47 space. CD47 is just like the PD or PD1 target that the current Immune Drugs go after. The key will be if they work together.

Look at ALXO and IMB along with Tril if your interested.

Good Luck